Browse the corpus

Measles is a highly contagious viral infection caused by the measles virus, primarily affecting the respiratory system and characterized by fever, cough, conjunctivitis, and a distinctive rash. Transmission occurs through respiratory droplets, making it easily spread in unvaccinated populations. Complications can include pneumonia, encephalitis, and, in rare cases, death, particularly in young children and immunocompromised individuals. The measles-mumps-rubella (MMR) vaccine effectively prevents measles by stimulating the immune system to produce antibodies against the live-attenuated virus. Routine immunization is recommended for children, adolescents, and adults born after 1957 without prior immunity, with specific indications for healthcare professionals, military personnel, and international travelers. Vaccination significantly reduces the incidence of measles and its complications, contributing to herd immunity. The course provides participants with comprehensive knowledge of the MMR vaccine’s indications, mechanism of action, administration protocols, and potential adverse reactions. Participants learn to identify suitable candidates for vaccination, including susceptible populations requiring post-exposure prophylaxis. The curriculum emphasizes safe administration techniques and patient education to promote vaccine acceptance. Collaboration with an interprofessional healthcare team, including physicians, nurses, pharmacists, and public health professionals, enhances patient outcomes by ensuring accurate vaccine delivery, addressing patient concerns, and coordinating follow-up care. This teamwork fosters a cohesive approach to immunization, improving compliance and reducing the risk of measles outbreaks across diverse clinical settings. Objectives: Identify eligible patients for measles-mumps-rubella vaccination based on current immunization guidelines, including those in pediatric, obstetric, and high-risk populations. Differentiate between indications and contraindications for measles-mumps-rubella vaccine administration to ensure safe use across diverse clinical scenarios Screen patients for prior immunity or vaccination history to determine the need for measles-mumps-rubella vaccination or post-exposure prophylaxis.

Identify eligible patients for measles-mumps-rubella vaccination based on current immunization guidelines, including those in pediatric, obstetric, and high-risk populations. Differentiate between indications and contraindications for measles-mumps-rubella vaccine administration to ensure safe use across diverse clinical scenarios Screen patients for prior immunity or vaccination history to determine the need for measles-mumps-rubella vaccination or post-exposure prophylaxis. Collaborate with other healthcare professionals to communicate effectively with patients and caregivers about the benefits, risks, and importance of measles-mumps-rubella vaccination to optimize patient outcomes. Access free multiple choice questions on this topic.

Limited data are available regarding the safety of administering an additional dose of the MMR vaccine. The administration of an additional dose of a vaccine may be necessary in cases where there is uncertainty about a person's vaccination history or due to programmatic errors, such as vaccination mistakes or errors in the vaccination process. Among 5067 reported instances of excess vaccine doses administered between 2007 and 2017, three-fourths of the cases did not result in adverse events following immunization. The most commonly reported adverse health events were pyrexia (12.8%), injection site erythema (9.7%), injection site pain (8.9%), and headache (6.6%). The percentage of adverse events among these cases was comparable to all cases submitted to the VAERS during the same study period.[25]

Vaccination with the MMR vaccine requires an interprofessional approach as the proper administration of the vaccine changes according to the patient population and the clinical scenario. The mumps outbreaks have increased in the US since 2006. Due to the resurgence of mumps and the risk associated with rubella and measles, increasing MMR coverage is necessary. The availability of MMR vaccines from different manufacturers ensures the continuous supply of vaccines.[6][26] Children with neurological diseases should be vaccinated following accepted rules and vaccination schedules. One should remember that the risk of severe infection, the need for hospitalization, and complications in children with chronic disease are significantly higher than in the healthy population. Additionally, each infection disrupts rehabilitation, adversely affecting the child's neurological status. Also, children with chronic diseases are more likely to be in healthcare facilities, increasing infection risk. Contraindications to MMR vaccination in children with neurological diseases are limited and temporary.[5] They include the following: Undetermined neurological diagnosis Suspicion of progressive central nervous system disease with epilepsy Six months after the last convulsive seizure Unstabilized neurological condition Contraindications to MMR vaccination do not include: Epilepsy with an excellent response to treatment (at least 6 months without seizures) A neurological disorder before the start of vaccination In children with epilepsy, the recommendation is to administer antipyretic drugs for 6 to 12 days after administration of MMR, as fever that may occur as an adverse reaction may trigger seizures.[2][3] Another recommendation is to educate patients with a multi-disciplinary team about vaccination's perceived but false risks. For example, the association of MMR with autism spectrum disorder (ASD) has aroused much controversy in recent years. Several antivaccine advocacy groups put the hypothesis linking autism and inflammatory bowel disease with MMR vaccination forward in the last century.[27]

In children with epilepsy, the recommendation is to administer antipyretic drugs for 6 to 12 days after administration of MMR, as fever that may occur as an adverse reaction may trigger seizures.[2][3] Another recommendation is to educate patients with a multi-disciplinary team about vaccination's perceived but false risks. For example, the association of MMR with autism spectrum disorder (ASD) has aroused much controversy in recent years. Several antivaccine advocacy groups put the hypothesis linking autism and inflammatory bowel disease with MMR vaccination forward in the last century.[27] In 1998, The Lancet published an article in which researchers reported a link between the MMR vaccine and intestinal leukemia. The article's basis was the temporal relationship between the increased ASD diagnoses (observed since the 1980s) and recommended childhood vaccines against Haemophilus influenzae type B, hepatitis B, chickenpox, pneumococci, influenza, and the MMR vaccine.[27][28] Smoking weakens both innate and adaptive immunity, potentially reducing vaccine efficacy across various formulations. The MMR vaccine remains vital for preventing measles, mumps, and rubella, but smoking may impair optimal antibody response.[29] The thesis put forward by Wakefield's team serves as the starting point for numerous epidemiological and prospective studies worldwide, which have ruled out a cause-and-effect relationship between vaccination (including MMR) and the occurrence of ASD or inflammatory bowel disease. Subsequent analysis proved that increased ASD diagnoses resulted from changes in ASD recognition criteria as a neurodevelopmental disorder and increasing awareness of this problem. Prospective studies have shown that ASD symptoms often occur in the first year of life, before the first dose of MMR.

The thesis put forward by Wakefield's team serves as the starting point for numerous epidemiological and prospective studies worldwide, which have ruled out a cause-and-effect relationship between vaccination (including MMR) and the occurrence of ASD or inflammatory bowel disease. Subsequent analysis proved that increased ASD diagnoses resulted from changes in ASD recognition criteria as a neurodevelopmental disorder and increasing awareness of this problem. Prospective studies have shown that ASD symptoms often occur in the first year of life, before the first dose of MMR. In 2004, a journalist revealed that Wakefield's test was conducted in a manner that did not follow medical ethics and was inaccurate. Most of the study's authors officially withdrew unreliable applications, and The Lancet completely retracted the article in 2010.[30] However, if adverse events occur following immunization, clinicians should report them through the VAERS.[31] Interprofessional coordination and collaboration among clinicians, specialists, pharmacists, nurses, and public health professionals can enhance patient outcomes when helping patients accept the MMR vaccine and prevent associated infections.